Skimming the surface Other May 29, 2025 Comparing median overall survival times is often the TL;DR takeaway when glancing at a trial evaluating oncologic therapies. Here is…
Endgame Other May 19, 2023 cross-sectional study asked a hard-hitting question: how often do oncology trialists commit the methodological sin of changing their primary endpoints…
Not so fast Other April 14, 2023 This editorial is here to once again remind us all that objective response rates and progression-free survival, while often endpoints…
Unrestricted Other April 11, 2023 Yet more data suggests restricted mean survival time may be the better endpoint than your standard median survival as it…
